ORCID as entered in ROS

Select Publications
2022, 'DISCOVERY AND PRE-CLINICAL DEVELOPMENT OF A NOVEL AND DIFFERENTIATED EPHA2-TARGETED ANTIBODY IN MULTIPLE BISPECIFIC FORMATS', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A1238 - A1238, http://dx.doi.org/10.1136/jitc-2022-SITC2022.1194
,2021, 'First-in-human phase 1b study of ATRC-101, a patient-derived antibody with a tumor-specific target, as monotherapy or in combination with pembrolizumab, in patients with solid tumors.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021
,2020, 'A psychological profile of near-centenarians and centenarians with and without dementia from the Sydney Centenarian Study', in INTERNATIONAL PSYCHOGERIATRICS, CAMBRIDGE UNIV PRESS, pp. 99 - 99, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000575131200078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'First-in-human phase Ib study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020
,2020, 'ATRC-101 DRIVES POTENT SINGLE-AGENT ACTIVITY IN MOUSE SYNGENEIC TUMOR MODELS VIA A NOVEL CELLULAR MECHANISM OF ACTION', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A413 - A414, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0689
,2020, 'COOPERATION BETWEEN CHECKPOINT INHIBITORS TARGETING THE PD-1/PD-L1 AXIS AND ATRC-101, A NOVEL CLINICAL-STAGE CANDIDATE FOR THE TREATMENT OF SOLID TISSUE MALIGNANCIES', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A286 - A287, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0469
,2018, 'Development and initial psychometric validation of the advisor experience survey.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, AZ, Phoenix, presented at ASCO Quality Care Symposium, AZ, Phoenix, 28 September 2018 - 29 September 2018, http://dx.doi.org/10.1200/JCO.2018.36.30_suppl.220
,2018, 'Increased somatic hypermutation in the immunoglobulin sequences of melanoma patients who have durable response to checkpoint inhibitor therapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-615
,2018, 'Mining the cancer immuno-responsome: The identification of functional antitumor antibodies from patients receiving checkpoint inhibitors', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-3966
,2017, 'Mining the periphery for tumor-relevant B and T cells', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMC
,2017, 'Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.4_suppl.155
,2017, 'The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, pp. S937 - S937, http://dx.doi.org/10.1016/j.jtho.2016.11.1289
,2016, 'Screening for psychosocial distress: A transformative journey.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e18176
,2016, 'Does physical function impact the acceptability of routine patient-reported outcome surveys in cancer patients?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, AZ, Phoenix, presented at ASCO Quality Care Symposium, AZ, Phoenix, 26 February 2016 - 27 February 2016, http://dx.doi.org/10.1200/jco.2016.34.7_suppl.67
,2016, 'Identifying tools for capturing the overall experience of dyspnea in a lung cancer population: The patient's perspective.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, AZ, Phoenix, presented at ASCO Quality Care Symposium, AZ, Phoenix, 26 February 2016 - 27 February 2016, http://dx.doi.org/10.1200/jco.2016.34.7_suppl.73
,2016, 'Patient preferences for research access to administrative data in Ontario', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Cancer Survivorship Symposium on Advancing Care and Research, CA, San Francisco, 15 January 2016 - 16 January 2016, http://dx.doi.org/10.1200/jco.2016.34.3_suppl.144
,2015, 'Are palliative patients less accepting to self-report symptom measures for clinical management than curative patients?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, MA, Boston, presented at Palliative Care in Oncology Symposium, MA, Boston, 09 October 2015 - 10 October 2015, http://dx.doi.org/10.1200/jco.2015.33.29_suppl.79
,2015, 'Comparison of prevalence of pain symptoms and completion rates using a patient-reported outcomes (PRO) tool of pain in palliative and curative patients', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, MA, Boston, presented at Palliative Care in Oncology Symposium, MA, Boston, 09 October 2015 - 10 October 2015, http://dx.doi.org/10.1200/jco.2015.33.29_suppl.78
,2015, 'Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.6607
,2015, 'EGFR and ALK Status Influence Health Utility and Global Quality of Life Scores in Patients with Metastatic Lung Cancer', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, pp. S704 - S704
,2015, 'Patient-Reported Health Utility Scores (HUS) in Non-small Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations by Drug Therapy', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY-BLACKWELL, pp. 52 - 52
,2011, 'THE POWER OF LEAN PLUS AUTOMATION TO INCREASE OPERATIONAL PRODUCTIVITY AND SAFETY IN PRETRANSFUSION TESTING', in VOX SANGUINIS, WILEY-BLACKWELL, pp. 48 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000296362800130&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'A flexible dual task paradigm for evaluating an embodied conversational agent: Modality effects and reaction time as an index of cognitive load', in Lecture Notes in Computer Science Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics, pp. 331 - 337, http://dx.doi.org/10.1007/978-3-642-23974-8_36
,2007, 'INOR 312-Photoactive manganese nitrosyls: Factors critical for controlling NO photorelease', in ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, AMER CHEMICAL SOC
,2006, 'INOR 734-Visible light activated release of nitric oxide from a sol-gel hybrid material containing a photoactive manganese nitrosyl', in ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, AMER CHEMICAL SOC
,